Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
LLEli Lilly and Company logo

Eli Lilly and Company (LLY)

New York Stock Exchange · Currency in USD
$1,273.46 ▼ -33.23 (-2.54%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1,277.30 ▲ +3.84 (+0.30%)
After hours: Oct 23, 7:52 PM ET

Summary

Previous Close
$1,306.69
Open
$1,304.15
Day's Range
$1,257.62 – $1,307.92
52 Week Range
$809.63 – $1,321.21
Volume
2,269,331
Avg. Volume
2,610,102
Market Cap
$1.20T
Beta (5Y Monthly)
0.45
PE Ratio (TTM)
42.60
EPS (TTM)
$29.93
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
$6.92 (0.54%)
Ex-Dividend Date
Aug 14, 2026
1y Target Est
$1,355.25

Profile: Eli Lilly and Company

Sector
Healthcare
Industry
Drug Manufacturers - General
Full-time employees
50,000
CEO
David A. Ricks
Website
lilly.com

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500).

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate $5.70 · Revenue est. $22.58B
DateEst.Actual
Aug 5, 2026$6.40$8.38Beat
Apr 30, 2026$6.97$8.55Beat
Feb 4, 2026$6.91$7.54Beat
Oct 30, 2025$5.69$7.02Beat
Aug 7, 2025$5.60$6.31Beat
May 1, 2025$3.26$3.34Beat

Analyst view

Consensus price target
$1,355.25 ▲ +6.4%
Range $940.00 – $1,500.00
Rating: Buy
Buy 73% · Hold 20% · Sell 7%

Get free alerts on LLY and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.